You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 20, 2024

Details for New Drug Application (NDA): 214919


✉ Email this page to a colleague

« Back to Dashboard


NDA 214919 describes GLYCOPYRROLATE, which is a drug marketed by Abraxis Pharm, Accord Hlthcare, Alembic, Am Regent, Amneal, Apotex, Caplin, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma Farmaceutica, Hospira, Lupin Ltd, Mankind Pharma, Meitheal, Omnivium Pharms, Piramal Critical, Prinston Inc, Sagent, Sandoz, Somerset Theraps Llc, Teva Parenteral, Umedica, Watson Labs, Xiromed, Zydus Pharms, Annora Pharma, Chartwell Rx, Endo Operations, Granules, Saptalis Pharms, Suven Pharms, Adaptis, Aurobindo Pharma, Dr Reddys Labs Ltd, Heritage Pharms Inc, Hikma Intl Pharms, Lgm Pharma, Natco, Oxford Pharms, Quagen, Rising, Sun Pharm Inds Ltd, and Velzen Pharma Pvt, and is included in fifty-five NDAs. It is available from fifty-one suppliers. Additional details are available on the GLYCOPYRROLATE profile page.

The generic ingredient in GLYCOPYRROLATE is glycopyrrolate. There are seventeen drug master file entries for this compound. Fifty-seven suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.
Summary for 214919
Tradename:GLYCOPYRROLATE
Applicant:Fresenius Kabi Usa
Ingredient:glycopyrrolate
Patents:0
Pharmacology for NDA: 214919
Medical Subject Heading (MeSH) Categories for 214919
Suppliers and Packaging for NDA: 214919
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
GLYCOPYRROLATE glycopyrrolate SOLUTION;INTRAMUSCULAR, INTRAVENOUS 214919 NDA Fresenius Kabi USA, LLC 76045-023 76045-023-30 10 SYRINGE in 1 CARTON (76045-023-30) / 3 mL in 1 SYRINGE (76045-023-00)
GLYCOPYRROLATE glycopyrrolate SOLUTION;INTRAMUSCULAR, INTRAVENOUS 214919 NDA Fresenius Kabi USA, LLC 76045-223 76045-223-30 10 SYRINGE in 1 CARTON (76045-223-30) / 3 mL in 1 SYRINGE (76045-223-03)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAMUSCULAR, INTRAVENOUSStrength0.6MG/3ML (0.2MG/ML)
Approval Date:Apr 21, 2022TE:RLD:Yes

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.